Male potency drug available in five weeks
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.VIAGRA, THE impotence drug, may be available on prescription in Britain in about five weeks.
A European Commission standing committee will hold the final licensing hearing in London today and, barring unforeseen complications, Pfizer, the British manufacturer of the drug, expects a "positive outcome".
A spokesman said: "This should be one of the last hurdles for us. We may well have to answer some additional questions during the hearing, but we think we can do that."
If there are no last-minute hitches, the licence recommendation will go forward tomorrow to a European Commissioner for rubber stamping. This process usually takes about two weeks.
"After that, Pfizer believes it will probably take another three weeks or so to organise distribution and all the legally required printed information for GPs in this country. So we are looking at starting to supply shops by around 6 September," the spokesman added.
Once the drug receives a licence, doctors will be able to prescribe the drug as they see fit, although patients will have to wait until at least next month to pick up the product.
Pfizer stresses that its scientists applied for a British licence in late summer last year, at exactly the same time they approached the authorities in the United States. However, due to the comparatively arcane nature of the European system, the drug has so far taken almost six months longer to get to the point of sale in Europe.
"It has been about a year since Pfizer first took the matter to the European Commission and that is a fairly average length of time for the licensing of any drug here," said the spokesman.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments